AstraZeneca PLC (ZEGA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AstraZeneca PLC (ZEGA) has a cash flow conversion efficiency ratio of 0.112x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€5.13 Billion ≈ $6.00 Billion USD) by net assets (€45.97 Billion ≈ $53.74 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
AstraZeneca PLC - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how AstraZeneca PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
AstraZeneca PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AstraZeneca PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Roche Holding AG
SW:ROP
|
0.296x |
|
Toyota Motor Corporation ADR
NYSE:TM
|
0.021x |
|
Philip Morris International Inc
NYSE:PM
|
-0.587x |
|
UnitedHealth Group Incorporated
NYSE:UNH
|
0.011x |
|
Toyota Motor Corporation
MX:TMN
|
0.021x |
|
Wells Fargo & Company
NYSE:WFC
|
-0.005x |
|
Westpac Banking Corporation
AU:WBCPI
|
-0.064x |
|
Royal Bank of Canada
TO:RY
|
-0.106x |
Annual Cash Flow Conversion Efficiency for AstraZeneca PLC (2014–2024)
The table below shows the annual cash flow conversion efficiency of AstraZeneca PLC from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €40.87 Billion ≈ $47.78 Billion |
€11.86 Billion ≈ $13.87 Billion |
0.290x | +9.68% |
| 2023-12-31 | €39.17 Billion ≈ $45.79 Billion |
€10.36 Billion ≈ $12.12 Billion |
0.265x | -0.03% |
| 2022-12-31 | €37.06 Billion ≈ $43.32 Billion |
€9.81 Billion ≈ $11.47 Billion |
0.265x | +74.37% |
| 2021-12-31 | €39.29 Billion ≈ $45.93 Billion |
€5.96 Billion ≈ $6.97 Billion |
0.152x | -50.54% |
| 2020-12-31 | €15.64 Billion ≈ $18.28 Billion |
€4.80 Billion ≈ $5.61 Billion |
0.307x | +50.87% |
| 2019-12-31 | €14.60 Billion ≈ $17.06 Billion |
€2.97 Billion ≈ $3.47 Billion |
0.203x | +9.12% |
| 2018-12-31 | €14.04 Billion ≈ $16.42 Billion |
€2.62 Billion ≈ $3.06 Billion |
0.186x | -13.30% |
| 2017-12-31 | €16.64 Billion ≈ $19.46 Billion |
€3.58 Billion ≈ $4.18 Billion |
0.215x | -13.54% |
| 2016-12-31 | €16.67 Billion ≈ $19.49 Billion |
€4.14 Billion ≈ $4.85 Billion |
0.249x | +38.46% |
| 2015-12-31 | €18.51 Billion ≈ $21.64 Billion |
€3.32 Billion ≈ $3.89 Billion |
0.180x | -50.01% |
| 2014-12-31 | €19.65 Billion ≈ $22.97 Billion |
€7.06 Billion ≈ $8.25 Billion |
0.359x | -- |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo,… Read more